The Motley Fool··Reuben Gregg BrewerGLP-1 Gold Rush: Which Weight-Loss Drug Stocks Offer Best Value in 2026
Eli Lilly dominates GLP-1 drugs at 35x P/E, while Novo Nordisk offers 10x P/E turnaround after 45% decline. Viking Therapeutics presents high-risk clinical bet.
LLYNVOVKTXclinical trialsGLP-1 drugs